Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study
Authors:
Open Access
- 23 May 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 26343
Abstract
Data on simultaneous analysis of human papillomavirus (HPV) DNA and serology and the correlations within a single general population are limited. Among 1603 men and 2187 women enrolled from rural China, serum antibodies against bacterially derived GST-L1 fusion proteins of HPV were assessed with multiplexed serology and HPV DNA was evaluated with PCR-based sequencing. Few subjects were dually positive to HPV DNA and serum antibodies for any HPV (6.6% of men and 3.1% of women). The proportion of men ever having been infected with any HPV (DNA and/or antibody positive) was higher than that of women (71.0% vs. 65.2%, P < 0.001). Type-specific association was observed for genital HPV infection and HPV seropositivity among women but not among men. A positive correlation between the number of lifetime sexual partners and positivity for oncogenic HPV DNA and/or antibodies was found in men but was absent in women. Among 762 couples, the presence of HPV DNA and/or antibodies in one partner was positively associated with the identical HPV type in the other partner. These findings may reflect a site-specific natural course of HPV infection and further understanding of the epidemiology of HPV.Keywords
This publication has 41 references indexed in Scilit:
- Seroprevalence of 10 human papillomavirus types in the general rural population of Anyang, China: a cross-sectional studySexually Transmitted Infections, 2015
- Patterns of Human Papillomavirus DNA and Antibody Positivity in Young Males and Females, Suggesting a Site-Specific Natural Course of InfectionPLOS ONE, 2013
- Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global ReviewJournal of Adolescent Health, 2012
- Population‐based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese womenInternational Journal of Cancer, 2011
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Carcinogenicity of human papillomavirusesThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up StudyAmerican Journal of Epidemiology, 2003
- Comparison of Human Papillomavirus Types 16, 18, and 6 Capsid Antibody Responses Following Incident InfectionThe Journal of Infectious Diseases, 2000
- Immunoglobulin G Responses Against Human Papillomavirus Type 16 Virus-Like Particles in a Prospective Nonintervention Cohort Study of Women With Cervical Intraepithelial NeoplasiaJNCI: Journal of the National Cancer Institute, 1997